



#46

PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: STEVENS, Fred J. et. al.  
Title: FIBRIL-BLOCKING PEPTIDE, A METHOD FOR PREVENTING FIBRIL FORMATION  
Serial No.: 09/712,819  
Filing Date: November 13, 2000  
Examiner: Dr. Phuong N. Huynh, Ph. D.  
Art Unit: 1644  
Atty Docket: 0003/00537

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first Class Mail, pursuant to 37 C.F.R. 1.8 to the Assistant Commissioner for Patents, Washington, D.C. 20231 on January 29, 2003 (Date of Deposit)

Michael J. Cherskov

Name of Representative

Signature of Representative

Date of Signature

ASSISTANT COMMISSIONER  
FOR PATENTS  
Washington, D.C. 20231

20 N. Wacker Drive  
Chicago, IL 60606  
312-621-1330

LETTER TO THE OFFICIAL DRAFTSPERSON

Dear Sir or Madam:

Enclosed please find two (2) sheets of formal drawing for Figures 1 and 3, submitted in response to the July 29, 2002 Office Action, wherein the Examiner indicated that prosecution on the merits is closed. Please substitute the enclosed drawing for the originally submitted drawing. This formal drawing rectifies the May 13, 2002 objections made by the Draftsperson.


No new matter has been added to this formal drawing.

A duplicate copy of this communication is enclosed.

Respectfully submitted,  
CHERSKOV & FLAYNIK

BY:

Michael J. Cherskov (Reg No. 33,664)



Application No.: 09/712,819

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: SEQ ID is Required for peptides "FTLEISR" and "LTLKLSR".

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**